

References

- Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, et al. Antifungal susceptibility profile of clinical *Fusarium* spp. isolates identified by molecular methods. *J Antimicrob Chemother* 2008; 61:805. ([HERE](#))
- Alfonso EC, Cantu-Dibildox J, Munir WM, et al. Insurgence of *Fusarium* keratitis associated with contact lens wear. *Arch Ophthalmol* 2006; 124:941. ([HERE](#))
- Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, et al. Specific antifungal susceptibility profiles of opportunists in the *Fusarium* fujikuroi complex. *J Antimicrob Chemother* 2015; 70:1068. ([HERE](#))
- Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic *Fusarium* species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. *Clin Infect Dis*. 2001 Dec 1;33(11):1871-8. ([HERE](#))
- Arikan S, Lozano-Chiu M, Paetznick V, et al. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of *Aspergillus* and *Fusarium* species. *J Clin Microbiol* 1999; 37:3946. ([HERE](#))
- Benish M, Elitzur S, Arad-Cohen N, et al. Invasive Fusariosis in Pediatric Hematology/Oncology and Stem Cell Transplant Patients: A Report from the Israeli Society of Pediatric Hematology-Oncology. *J Fungi (Basel)* 2022; 8. ([HERE](#))
- Bose P, Parekh HD, Holter JL, et al. Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis. *J Clin Microbiol* 2011; 49:1674. ([HERE](#))
- Boutati EI, Anaissie EJ. *Fusarium*, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. *Blood* 1997; 90:999. ([HERE](#))
- Carlesse F, Amaral AC, Gonçalves SS, et al. Outbreak of *Fusarium oxysporum* infections in children with cancer: an experience with 7 episodes of catheter-related fungemia. *Antimicrob Resist Infect Control* 2017; 6:93. ([HERE](#))
- CDC. Mycotic Diseases Branch. [Outbreak of Fungal Meningitis in U.S. Patients Who Underwent Surgical Procedures under Epidural Anesthesia in Matamoros, Mexico](#). Accessed 6/15/2023.
- Centers for Disease Control and Prevention (CDC). *Fusarium* keratitis--multiple states, 2006. *MMWR Morb Mortal Wkly Rep* 2006; 55:400. ([HERE](#))
- Córdoba S, Rodero L, Vivot W, et al. In vitro interactions of antifungal agents against clinical isolates of *Fusarium* spp. *Int J Antimicrob Agents* 2008; 31:171. ([HERE](#))
- Davison SP, Hayes KD, LaBove G, et al. The Price of Medical Tourism: The Legal Implications of Surgery Abroad. *Plast Reconstr Surg*. 2018 Oct;142(4):1075-1080. ([HERE](#))
- Debourgogne A, de Hoog S, Lozniewski A, et al. Amphotericin B and voriconazole susceptibility profiles for the *Fusarium solani* species complex: comparison between the E-test and CLSI M38-A2 microdilution methodology. *Eur J Clin Microbiol Infect Dis* 2012; 31:615. ([HERE](#))
- Dignani MC, Anaissie E. Human fusariosis. *Clin Microbiol Infect* 2004; 10 Suppl 1:67. ([HERE](#))

Dóczy I, Gyetvai T, Kredics L, et al. Involvement of *Fusarium* spp. in fungal keratitis. *Clin Microbiol Infect* 2004; 10:773. ([HERE](#))

Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated *Fusarium* infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. *J Clin Microbiol* 2003; 41:4898. ([HERE](#))

Eljaschewitsch J, Sandfort J, Tintelnot K, et al. Port-a-cath-related *Fusarium oxysporum* infection in an HIV-infected patient: treatment with liposomal amphotericin B. *Mycoses* 1996; 39:115. ([HERE](#))

Evans J, Levesque D, de Lahunta A, Jensen HE. Intracranial fusariosis: a novel cause of fungal meningoencephalitis in a dog. *Vet Pathol* 2004; 41:510. ([HERE](#))

Fisher MC, Hawkins NJ, Sanglard D, et al. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. *Science*. 2018 May 18;360(6390):739-742. ([HERE](#))

Foley BM, Haglin JM, Tanzer JR, et al. Patient care without borders: a systematic review of medical and surgical tourism. *J Travel Med*. 2019 Sep 2;26(6):taz049. ([HERE](#))

Gamis AS, Gudnason T, Giebink GS, et al. Disseminated infection with *Fusarium* in recipients of bone marrow transplants. *Rev Infect Dis* 1991; 13:1077. ([HERE](#))

Górska K, Blaszkowska J, Dzikowiec M. Neuroinfections caused by fungi. *Infection*. 2018 Aug;46(4):443-459. doi: 10.1007/s15010-018-1152-2. Epub 2018 May 21. ([HERE](#))

Guilhermetti E, Takahachi G, Shinobu CS, et al. *Fusarium* spp. as agents of onychomycosis in immunocompetent hosts. *Int J Dermatol* 2007; 46:822. ([HERE](#))

Gupta AK, Baran R, Summerbell RC. *Fusarium* infections of the skin. *Curr Opin Infect Dis* 2000; 13:121. ([HERE](#))

Guzman-Cottrill JA, Zheng X, Chadwick EG. *Fusarium solani* endocarditis successfully treated with liposomal amphotericin B and voriconazole. *Pediatr Infect Dis J* 2004; 23:1059. ([HERE](#))

Herbrecht R, Kessler R, Kravanja C, et al. Successful treatment of *Fusarium proliferatum* pneumonia with posaconazole in a lung transplant recipient. *J Heart Lung Transplant* 2004; 23:1451. ([HERE](#))

Ho DY, Lee JD, Rosso F, et al. Treating disseminated fusariosis: amphotericin B, voriconazole or both? *Mycoses* 2007; 50:227. ([HERE](#))

Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis. *Clinical Infectious Diseases*. 2011;52(6):750-770. ([HERE](#))

Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. *Antimicrob Agents Chemother* 2010; 54:4446. ([HERE](#))

Lupinetti FM, Giller RH, Trigg ME. Operative treatment of *Fusarium* fungal infection of the lung. *Ann Thorac Surg* 1990; 49:991. ([HERE](#))

Lyons JL, Roos KL, Marr KA, et al. Cerebrospinal Fluid (1,3)- β -d -Glucan Detection as an Aid for Diagnosis of Latrogenic Fungal Meningitis. *J Clin Microbiol*. 2013;51(4):1285-1287. ([HERE](#))

Martino P, Gastaldi R, Raccach R, et al. Clinical patterns of Fusarium infections in immunocompromised patients. *J Infect* 1994; 28 Suppl 1:7. ([HERE](#))

McCarthy M, Rosengart A, Schuetz AN, et al. Mold infections of the central nervous system. *N Engl J Med* 2014; 371:150. ([HERE](#))

Meningitis – Resources for Healthcare Professionals. Centers for Disease Control and Prevention. Accessed 06/15/2023. <https://www.cdc.gov/meningitis/index.html>

Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. *Clin Microbiol Rev* 1994; 7:479. ([HERE](#))

Njambi S, Huttova M, Kovac M, et al. Fungal neuroinfections: rare disease but unacceptably high mortality. *Neuro Endocrinol Lett*. 2007 Jun;28 Suppl 2:25-6. ([HERE](#))

Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. *Clin Infect Dis* 2002; 35:909. ([HERE](#))

Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. *Clin Microbiol Rev* 2007; 20:695. ([HERE](#))

Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. *Cancer* 2003; 98:315. ([HERE](#))

Nucci M, Marr KA, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. *Clin Microbiol Infect* 2014; 20:580. ([HERE](#))

Ortoneda M, Capilla J, Javier Pastor F, et al. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. *Diagn Microbiol Infect Dis* 2004; 48:69. ([HERE](#))

Pan American Health Organization. Technical Note: Meningitis of unknown origin Mexico. <https://www.paho.org/en/documents/technical-note-meningitis-unknown-origin-mexico>.

Pfaffer MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond *Candida albicans* and *Aspergillus fumigatus*. *J Clin Microbiol* 2004; 42:4419. ([HERE](#))

Runnels V, Carrera PM. Why do patients engage in medical tourism? *Maturitas*. 2012 Dec;73(4):300-4. ([HERE](#))

Schwartz S, Kontoyiannis DP, Harrison T, et al. Advances in the diagnosis and treatment of fungal infections of the CNS. *Lancet Neurol*. 2018 Apr;17(4):362-72. ([HERE](#))

Šišić A, Baćanović-Šišić J, Al-Hatmi AMS, et al. The 'forma specialis' issue in Fusarium: A case study in *Fusarium solani* f. sp. pisi. *Sci Rep*. 2018 Jan 19;8(1):1252. ([HERE](#))

Smith RM, Schaefer MK, Kainer MA, et al. Fungal Infections Associated with Contaminated Methylprednisolone Injections. *N Engl J Med*. 2013;369(17):1598-1609. ([HERE](#))

Venditti M, Micozzi A, Gentile G, et al. Invasive *Fusarium solani* infections in patients with acute leukemia. *Rev Infect Dis* 1988; 10:653. ([HERE](#))

Wickern GM. Fusarium allergic fungal sinusitis. *J Allergy Clin Immunol* 1993; 92:624. ([HERE](#))

